Literature DB >> 2545862

Relationship between biotransformation of glyceryl trinitrate and cyclic GMP accumulation in various cultured cell lines.

B M Bennett1, D C Leitman, H Schröder, J H Kawamoto, K Nakatsu, F Murad.   

Abstract

We assessed glyceryl trinitrate (GTN) biotransformation and cyclic GMP accumulation in cultured rat lung fibroblasts (RLF), porcine kidney epithelial (PK1), bovine aortic endothelial (BAE) and bovine aortic smooth muscle (BASM) cells. Biotransformation of 0.1 microM GTN was linear over 30 min and the percentage of glyceryl dinitrate (GDN)/10(6) cells for BAE, BASM, RLF and PK1 at 30 min was 3.1, 2.3, 5.8 and 21.7%, respectively. At low GTN concentration (0.01-0.1 microM) there was a highly selective formation of 1,2-GDN, whereas at higher GTN concentration (greater than 1 microM) this selectivity was lost. Cyclic GMP accumulation did not occur in BAE or BASM at any GTN concentration, whereas for RLF and PK1 it was highly correlated to the rate of GDN formation. Upon re-exposure to GTN after treatment of RLF or PK1 cells for 3 hr with 0.1 mM GTN, there was an almost complete loss of the cyclic GMP response, GTN biotransformation was attenuated markedly and the selective formation of 1,2-GDN at low GTN concentration was absent. However, when GTN-treated cells were incubated for 18 hr in GTN-free media, there was a recovery of the cyclic GMP response, GTN biotransformation and selective 1,2-GDN formation toward control values.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2545862

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  12 in total

1.  The nitric oxide donor SIN-1 is free of tolerance and maintains its cyclic GMP stimulatory potency in nitrate-tolerant LLC-PK1 cells.

Authors:  B Hinz; H Schröder
Journal:  Pharm Res       Date:  1999-05       Impact factor: 4.200

2.  Investigation of a cellular pharmacodynamic model exhibiting sharp response sensitivity and tolerance.

Authors:  Ronald A Siegel
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-12-12       Impact factor: 2.745

3.  On-line measurement of nitric oxide release from organic nitrates in the intact coronary circulation.

Authors:  K Schrör; S Förster; I Woditsch
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-08       Impact factor: 3.000

Review 4.  Recent developments in nitric oxide donor drugs.

Authors:  M R Miller; I L Megson
Journal:  Br J Pharmacol       Date:  2007-04-02       Impact factor: 8.739

5.  Effect of overexpression of human aldehyde dehydrogenase 2 in LLC-PK1 cells on glyceryl trinitrate biotransformation and cGMP accumulation.

Authors:  Y D'Souza; Y Ji; B M Bennett
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

6.  Changes in aldehyde dehydrogenase 2 expression in rat blood vessels during glyceryl trinitrate tolerance development and reversal.

Authors:  Y D'Souza; S Dowlatshahi; B M Bennett
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

7.  Variable glyceryl dinitrate formation following infusions of glyceryl trinitrate at different vascular sites in the rat.

Authors:  E Nakashima; D T Lau; L Z Benet
Journal:  Pharm Res       Date:  1991-07       Impact factor: 4.200

8.  Role of glutaredoxin-mediated protein S-glutathionylation in cellular nitroglycerin tolerance.

Authors:  Pei-Suen Tsou; Vamsi Addanki; Jessica A Haas; Nathaniel A Page; Ho-Leung Fung
Journal:  J Pharmacol Exp Ther       Date:  2009-02-17       Impact factor: 4.030

9.  Dissociation between superoxide accumulation and nitroglycerin-induced tolerance.

Authors:  Pei-Suen Tsou; Vamsi Addanki; Ho-Leung Fung
Journal:  J Pharmacol Exp Ther       Date:  2008-07-24       Impact factor: 4.030

10.  Different effects of ascorbate deprivation and classical vascular nitrate tolerance on aldehyde dehydrogenase-catalysed bioactivation of nitroglycerin.

Authors:  M V Wenzl; G Wölkart; H Stessel; M Beretta; K Schmidt; B Mayer
Journal:  Br J Pharmacol       Date:  2009-02-27       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.